1
|
Hopkins M, Arcenas R, Couto-Parada X, Lewinski M, Njoya M, Perinpanathan D, Sheriff R, Hansra A, Singh S. PivNG primers and probes set used in the cobas omni Utility Channel is a reliable supplemental test for detection of Neisseria gonorrhoeae in oropharyngeal, urogenital and rectal specimens collected in cobas PCR Media. Sex Transm Infect 2023; 99:416-419. [PMID: 37116988 PMCID: PMC10447364 DOI: 10.1136/sextrans-2022-055576] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Accepted: 04/01/2023] [Indexed: 04/30/2023] Open
Abstract
OBJECTIVE To evaluate the clinical performance of the novel PivNG primers and probes set (PivNG test) used in the cobas omni Utility Channel for supplemental testing of Neisseria gonorrhoeae (NG). METHODS Oropharyngeal, urogenital and rectal samples were self-collected during routine testing at Barts Health sexual health clinics, London, UK. Samples were tested by the cobas CT/NG test and PivNG cobas omni Utility Channel test on cobas 6800/8800 Systems. Supplemental testing was carried out with the Xpert CT/NG test. PivNG overall percent agreements, positive percent agreements (PPAs)/negative percent agreements (NPAs) and positive/negative predictive values were calculated for each sample type. Microscopy and/or culture data were included for a randomised subset of concordant/discordant results, and a composite reference standard (cobas CT/NG, Xpert CT/NG and culture results) adjusted for partial verification bias was used to determine PivNG PPA and NPA. RESULTS Of 447 evaluable samples with valid results from all three assays (cobas CT/NG, PivNG and Xpert CT/NG), 288 (64.4%) were NG-positive by both PivNG and cobas CT/NG; 117 (26.2%) were NG-negative in both tests; and 42 (9.4%) had discordant results (with NG-negative supplementary Xpert) CT/NG results in 40/42 instances). Of 19 PivNG/Xpert CT/NG-discordant samples, 11 were confirmed NG-positive by microscopy and/or culture results. PivNG PPA and NPA were 100% and 91% for oropharyngeal swabs, 100% and 100% for vaginal swabs, 100% and 100% for male urine samples, and 100% and 97% for rectal swabs, respectively, compared with the partially adjusted composite reference standard. CONCLUSIONS PivNG is a reliable supplementary test with high sensitivity for confirming NG infection when used in conjunction with the cobas CT/NG test and samples collected in cobas PCR Media. Moreover, the PivNG test offers a convenient, high-throughput solution for supplemental NG testing of various sample types, with the potential to reduce the number of indeterminate reports.
Collapse
Affiliation(s)
- Mark Hopkins
- Department of Infection and Immunity, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
- Department of Infection and Immunity, Barts Health NHS Trust, London, UK
| | - Rodney Arcenas
- Roche Molecular Systems Inc, Pleasanton, California, USA
| | - Xose Couto-Parada
- Department of Infection and Immunity, Barts Health NHS Trust, London, UK
| | | | - Merlin Njoya
- Roche Molecular Systems Inc, Pleasanton, California, USA
| | - Deva Perinpanathan
- Department of Infection and Immunity, Barts Health NHS Trust, London, UK
| | - Rizwaan Sheriff
- Department of Infection and Immunity, Barts Health NHS Trust, London, UK
| | - Avneet Hansra
- Roche Molecular Systems Inc, Pleasanton, California, USA
| | - Selena Singh
- Department of Infection and Immunity, Barts Health NHS Trust, London, UK
| |
Collapse
|
2
|
A previously documented Neisseria macacae isolate providing a false-positive result with Roche cobas 4800 CT/NG does not cross-react with the later generation cobas 6800 CT/NG assay. Eur J Clin Microbiol Infect Dis 2023; 42:121-123. [PMID: 36372865 DOI: 10.1007/s10096-022-04519-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Accepted: 10/31/2022] [Indexed: 11/15/2022]
|
3
|
Matsumoto M, Hamasuna R, Le PT, Fujimoto N, Matsumoto T. Detection of Neisseria gonorrhoeae or Chlamydia trachomatis from oral wash specimens using the Abbott RealTime CT/NG assay and the Cobas 4800 CT/NG assay: A prospective study. J Infect Chemother 2021; 28:480-485. [PMID: 34930626 DOI: 10.1016/j.jiac.2021.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Revised: 11/24/2021] [Accepted: 12/08/2021] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Isolating oropharyngeal Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) from oral wash specimens (OWSs) is uncommon. Therefore, we evaluated the performance of the Abbott RealTime CT/NG assay and the Cobas 4800 CT/NG assay in detecting NG and CT in OWSs. METHODS This multicenter prospective study included 457 patients from 14 medical facilities suspected of having untreated male urethritis or female cervicitis from November 2014 to December 2015. OWSs were collected and tested using the Abbott and Cobas assays. Finally, the discordant results were confirmed using the APTIMA Combo 2 transcription-mediated amplification assay and retested using each assay. RESULTS The sensitivity and specificity of the Abbott assay were 100% and 97.2% for NG and 87.5% and 100% for CT, respectively, and of the Cobas assay were 100% and 98.8% for NG and 93.8% and 99.8% for CT, respectively. Both assays had high negative but low positive predictive values for oropharyngeal NG (Abbott assay: 65.7%, Cobas assay: 82.1%). Based on the definition of "true positive," the prevalence of oropharyngeal NG and CT were 5.0% and 3.5%, respectively. CONCLUSIONS The Abbott and Cobas assays using OWSs had high sensitivity and specificity, which can help diagnose oropharyngeal NG and CT. We consider that if a positive result is obtained, the patient should be treated because the negative predictive values were high. However, limited data are available on oropharyngeal NG and CT detection, and further studies are needed to clarify the role of oropharyngeal sexually transmitted infections.
Collapse
Affiliation(s)
- Masahiro Matsumoto
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
| | - Ryoichi Hamasuna
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan; Department of Urology, Federation of National Public Service Personnel Mutual Aid Associations, Shin-Kokura Hospital, Kitakyushu, Japan
| | - Phuong Thi Le
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Naohiro Fujimoto
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Tetsuro Matsumoto
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| |
Collapse
|
4
|
Doernberg SB, Komarow L, Tran TTT, Sund Z, Pandori MW, Jensen D, Tsalik EL, Deal CD, Chambers HF, Fowler VG, Evans SR, Patel R, Klausner JD. Simultaneous Evaluation of Diagnostic Assays for Pharyngeal and Rectal Neisseria gonorrhoeae and Chlamydia trachomatis Using a Master Protocol. Clin Infect Dis 2021; 71:2314-2322. [PMID: 31734695 PMCID: PMC7713680 DOI: 10.1093/cid/ciz1105] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Accepted: 11/08/2019] [Indexed: 01/08/2023] Open
Abstract
Background Pharyngeal and rectal Neisseria gonorrhoeae and Chlamydia trachomatis play important roles in infection and antibacterial resistance transmission, but no US Food and Drug Administration (FDA)–cleared assays for detection at these sites existed prior to this study. The objective was to estimate performance of assays to detect those infections in pharyngeal and rectal specimens to support regulatory submission. Methods We performed a cross-sectional, single-visit study of adults seeking sexually transmitted infection testing at 9 clinics in 7 states. We collected pharyngeal and rectal swabs from participants. The primary outcome was positive and negative percent agreement for detection of N. gonorrhoeae and C. trachomatis for 3 investigational assays compared to a composite reference. Secondary outcomes included positivity as well as positive and negative predictive values and likelihood ratios. Subgroup analyses included outcomes by symptom status and sex. Results A total of 2598 participants (79% male) underwent testing. We observed N. gonorrhoeae positivity of 8.1% in the pharynx and 7.9% in the rectum and C. trachomatis positivity of 2.0% in the pharynx and 8.7% in the rectum. Positive percent agreement ranged from 84.8% to 96.5% for different anatomic site infection combinations, whereas negative percent agreement was 98.8% to 99.6%. Conclusions This study utilized a Master Protocol to generate diagnostic performance data for multiple assays from different manufacturers in a single study population, which ultimately supported first-in-class FDA clearance for extragenital assays. We observed very good positive percent agreement when compared to a composite reference method for the detection of both pharyngeal and rectal N. gonorrhoeae and C. trachomatis. Clinical Trials Registration NCT02870101.
Collapse
Affiliation(s)
| | - Lauren Komarow
- The George Washington University Biostatistics Center, Rockville, Maryland, USA
| | - Thuy Tien T Tran
- The George Washington University Biostatistics Center, Rockville, Maryland, USA
| | - Zoe Sund
- Duke University, Durham, North Carolina, USA
| | - Mark W Pandori
- Alameda County Department of Public Health, Oakland, California, USA
| | | | - Ephraim L Tsalik
- Duke University, Durham, North Carolina, USA.,Durham Veterans Affairs Health Care System, Durham, North Carolina, USA
| | - Carolyn D Deal
- National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | | | | | - Scott R Evans
- The George Washington University Biostatistics Center, Rockville, Maryland, USA
| | | | | |
Collapse
|
5
|
Wang QY, Zheng LQ, Li RH, Zheng Y, Chen X, Li Q. Clinician-collected urethra swab: A good alternative sample type using cobas 4800 system for Chlamydia trachomatis and Neisseria gonorrhoeae in men. J Clin Lab Anal 2020; 34:e23331. [PMID: 32841434 PMCID: PMC7521308 DOI: 10.1002/jcla.23331] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 02/21/2020] [Accepted: 03/16/2020] [Indexed: 11/28/2022] Open
Abstract
Background Nucleic acid amplification tests (NAATs) are being used increasing to detection of CT (Chlamydia trachomatis) and NG (Neisseria gonorrhoeae) infections for superior sensitivity and specificity than other tests. Male first‐void urine (FVU) sample is the optimal sample type for detection of CT and NG by NAATs. Although not being the recommended by NAATs, clinician‐collected urethra swab (CCUS) is perhaps a good alternative sample type compared with the FVU sample in men. Methods Paired samples (FVU and CCUS) from one hundred male outpatients were simultaneously detected by urine pattern and swab pattern using cobas 4800 CT/NG assay on cobas 4800 system for the detection of CT and NG, respectively. And twenty‐one positive controls were also detected on cobas 4800 system. Results The CT/NG cycle thresholds (Ct) value of urine pattern is lower than that of swab pattern for the same positive samples (clinical samples and positive controls) on the cobas 4800 CT/NG assay. The final CT/NG results of two sample patterns from patients were highly consistent except for four discordant results. Conclusion CCUS is validated for a good alternative sample type for the CT/NG detection on the cobas 4800 system in this study.
Collapse
Affiliation(s)
- Qing-Yong Wang
- Department of Clinical Laboratory, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China
| | - Lu-Qing Zheng
- Department of Clinical Laboratory, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China
| | - Rong-Hai Li
- Department of Clinical Laboratory, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China
| | - Ying Zheng
- Department of Clinical Laboratory, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China
| | - Xun Chen
- Department of Clinical Laboratory, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China
| | - Qi Li
- Department of Clinical Laboratory, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China
| |
Collapse
|
6
|
Pryce TM, Hiew VJ, Haygarth EJ, Whiley DM. Second- and third-generation commercial Neisseria gonorrhoeae screening assays and the ongoing issues of false-positive results and confirmatory testing. Eur J Clin Microbiol Infect Dis 2020; 40:67-75. [PMID: 32767178 DOI: 10.1007/s10096-020-04004-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Accepted: 07/30/2020] [Indexed: 10/23/2022]
Abstract
Supplementary nucleic acid amplification tests for Neisseria gonorrhoeae (NG) are widely used to circumvent specificity problems often associated with extragenital sites. This study was prompted by our observations and concerns from local sexual health physicians over increased discrepancies between Roche cobas 4800 CT/NG (c4800) and our in-house supplementary NG-PCR (NG-duplex) for oropharyngeal samples, when compared with Abbott RealTime CT/NG (m2000) performed prior. Here, we investigated these differences. Three banks of NG-positive samples were used. Bank 1 (n = 344) were screened using m2000. Banks 2 (n = 344) and 3 (n = 400) were screened using c4800. Remnant nucleic acids from all banks were tested using NG-duplex as part of routine testing. Bank 2 samples were further tested using m2000, some selectively tested using Cepheid Xpert CT/NG. Bank 3 samples were further tested using cobas CT/NG (cobas 6800 system). Confirmatory rates were significantly (p < 0.0001) higher for m2000 compared with c4800, with oropharyngeal samples the key difference. However, we also showed that our NG-duplex failed to confirm some true-positive NG samples. Using an expanded gold standard, confirmatory rates for m2000 and c4800 exceeded 90% for all anatomical sites with the exception of c4800 for oropharyngeal specimens at 78%. The observed discrepancies were due to a combination of c4800 producing false-positive results for oropharyngeal samples as well as sensitivity issues related to the NG-duplex assay. The data highlight the ongoing need for NG supplemental nucleic acid testing for oropharyngeal samples but also emphasise the need for careful selection of supplementary methods.
Collapse
Affiliation(s)
- Todd M Pryce
- Department of Clinical Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, 9 Robin Warren Drive, Murdoch, Western Australia, 6150, Australia.
| | - Valerie J Hiew
- Department of Clinical Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, 9 Robin Warren Drive, Murdoch, Western Australia, 6150, Australia
| | - Erin J Haygarth
- Department of Clinical Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, 9 Robin Warren Drive, Murdoch, Western Australia, 6150, Australia
| | - David M Whiley
- Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia
| |
Collapse
|
7
|
Meyer T, Buder S. The Laboratory Diagnosis of Neisseria gonorrhoeae: Current Testing and Future Demands. Pathogens 2020; 9:E91. [PMID: 32024032 PMCID: PMC7169389 DOI: 10.3390/pathogens9020091] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Revised: 01/28/2020] [Accepted: 01/29/2020] [Indexed: 02/05/2023] Open
Abstract
The ideal laboratory test to detect Neisseria gonorrhoeae (Ng) should be sensitive, specific, easy to use, rapid, and affordable and should provide information about susceptibility to antimicrobial drugs. Currently, such a test is not available and presumably will not be in the near future. Thus, diagnosis of gonococcal infections presently includes application of different techniques to address these requirements. Microscopy may produce rapid results but lacks sensitivity in many cases (except symptomatic urogenital infections in males). Highest sensitivity to detect Ng was shown for nucleic acid amplification technologies (NAATs), which, however, are less specific than culture. In addition, comprehensive analysis of antibiotic resistance is accomplished only by in vitro antimicrobial susceptibility testing of cultured isolates. As a light at the end of the tunnel, new developments of molecular techniques and microfluidic systems represent promising opportunities to design point-of-care tests for rapid detection of Ng with high sensitivity and specificity, and there is reason to hope that such tests may also provide antimicrobial resistance data in the future.
Collapse
Affiliation(s)
- Thomas Meyer
- Department of Dermatology, Venerology and Allergology, St. Josef Hospital, Ruhr-University, 44791 Bochum, Germany
| | - Susanne Buder
- German Consiliary Laboratory for Gonococci, Department of Dermatology and Venerology, Vivantes Hospital Berlin, 12351 Berlin, Germany;
| |
Collapse
|
8
|
Factors That Influence Confirmation of Neisseria gonorrhoeae Positivity by Molecular Methods. J Clin Microbiol 2019; 57:JCM.02068-18. [PMID: 30944196 DOI: 10.1128/jcm.02068-18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2018] [Accepted: 03/26/2019] [Indexed: 11/20/2022] Open
Abstract
Several Neisseria gonorrhoeae nucleic acid amplification tests (NAATs) with high sensitivity exist. However, the specificity of N. gonorrhoeae NAATs may be suboptimal, particularly for extragenital biospecimens. Consequently, confirmation with a second NAAT is common, although this represents a burden on resources. Furthermore, the rationale for confirmation is contentious. The objective of this work was to assess N. gonorrhoeae confirmation in over 13,000 N. gonorrhoeae screen-positive samples representing various biospecimens and three separate screening assays, the Abbott RealTime CT/NG (Abbott Molecular, Inc., Des Plaines, IL), the Cobas CT/NG test (Roche Molecular Systems Inc., Alameda, CA), and the BD ProbeTec ET CT/GC amplified DNA assay (BD Diagnostics, Sparks, MD). Factors predictive of confirmation were determined via logistic regression involving sex, year, whether the sample was formally validated, and sample site. Level of confirmation varied according to screening assay (96.2%, 86.0%, and 73.9% for the Abbott, Roche, and BD tests, respectively) in sample types formally included according to the manufacturers' instructions (i.e., validated). Sex did not affect confirmation for 2/3 assays, and the likelihood of confirmation of samples not formally included in manufacturer instructions (i.e., nonvalidated) was 89.1%, 82.1%, and 59.2% for the Abbott, Roche, and BD tests, respectively. Rectal swabs, which are nonvalidated samples, confirmed in 91.5%, 90.1%, and 87.4% of samples initially tested with the respective assays. The requirement to confirm N. gonorrhoeae in validated samples is not required for all NAATs, although initial assay-specific evaluation is justified given observed variability. Rectal samples represent robust biospecimens for N. gonorrhoeae NAAT testing and may not require confirmation when screened with the assays described.
Collapse
|
9
|
Chow EPF, Walker S, Hocking JS, Bradshaw CS, Chen MY, Tabrizi SN, Howden BP, Law MG, Maddaford K, Read TRH, Lewis DA, Whiley DM, Zhang L, Grulich AE, Kaldor JM, Cornelisse VJ, Phillips S, Donovan B, McNulty AM, Templeton DJ, Roth N, Moore R, Fairley CK. A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol. BMC Infect Dis 2017; 17:456. [PMID: 28659133 PMCID: PMC5490220 DOI: 10.1186/s12879-017-2541-3] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Accepted: 06/09/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Gonorrhoea is one of the most common sexually transmissible infections in men who have sex with men (MSM). Gonorrhoea rates have increased substantially in recent years. There is concern that increasing gonorrhoea prevalence will increase the likelihood of worsening antibiotic resistance in Neisseria gonorrhoeae. A recent randomised controlled trial (RCT) demonstrated that a single-dose of mouthwash has an inhibitory effect against oropharyngeal gonorrhoea. We are conducting the first RCT to evaluate whether daily use of mouthwash could reduce the risk of acquiring oropharyngeal gonorrhoea. METHODS/DESIGN The OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study is a double-blind RCT and will be conducted at several sexual health clinics and high caseload General Practice (GP) clinics in Melbourne and Sydney, Australia. A total of 504 MSM attending the participating sites will be recruited. Participants will be randomised to either using 'Study mouthwash A' or 'Study mouthwash B' for 12 weeks. Study mouthwash A was inhibitory against N. gonorrhoeae in vitro, whereas study mouthwash B was not. Participants will be instructed to rinse and gargle the study mouthwash for 60 seconds every day. The primary outcome is the proportion of participants with oropharyngeal gonorrhoea detected by nucleic acid amplification test by 12 weeks. DISCUSSION The results from this trial may provide a novel way to reduce gonorrhoea prevalence and transmission without the use of antibiotics that may be associated with development of resistance. If shown to be effective, the widespread use of mouthwash will reduce the prevalence of oropharyngeal gonorrhoea, which plays key role in driving the emergence of gonococcal antimicrobial resistance through DNA exchange with oral commensal bacteria. The anticipated net effect will be interruption of onward transmission of N. gonorrhoeae within high density sexual networks within MSM populations. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12616000247471 , registered on 23rd February 2016.
Collapse
Affiliation(s)
- Eric P. F. Chow
- Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, VIC 3053 Australia
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004 Australia
| | - Sandra Walker
- Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, VIC 3053 Australia
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004 Australia
| | - Jane S. Hocking
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC 3053 Australia
| | - Catriona S. Bradshaw
- Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, VIC 3053 Australia
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004 Australia
| | - Marcus Y. Chen
- Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, VIC 3053 Australia
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004 Australia
| | - Sepehr N. Tabrizi
- Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Parkville, VIC 3052 Australia
- Murdoch Childrens Research Institute, Parkville, VIC 3052 Australia
- Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, VIC 3052 Australia
| | - Benjamin P. Howden
- Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, The University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3010 Australia
| | - Matthew G. Law
- Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, NSW 2150 Australia
| | - Kate Maddaford
- Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, VIC 3053 Australia
| | - Tim R. H. Read
- Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, VIC 3053 Australia
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004 Australia
| | - David A. Lewis
- Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, NSW 2150 Australia
- Marie Bashir Institute for Infectious Diseases and Biosecurity & Sydney Medical School-Westmead, The University of Sydney, Westmead, NSW 2145 Australia
| | - David M. Whiley
- Pathology Queensland Central Laboratory, QLD, Brisbane, 4029 Australia
- The University of Queensland Centre for Clinical Research, Royal Brisbane and Women’s Hospital Campus, QLD, Herston, 4029 Australia
| | - Lei Zhang
- Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, VIC 3053 Australia
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004 Australia
| | | | | | - Vincent J. Cornelisse
- Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, VIC 3053 Australia
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004 Australia
- Prahran Market Clinic, Prahran, VIC 3181 Australia
| | - Samuel Phillips
- Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Parkville, VIC 3052 Australia
- Murdoch Childrens Research Institute, Parkville, VIC 3052 Australia
| | - Basil Donovan
- The Kirby Institute, UNSW Sydney, Kensington, NSW 2052 Australia
- Sydney Sexual Health Centre, Sydney Hospital, Sydney, NSW 2000 Australia
| | - Anna M. McNulty
- Sydney Sexual Health Centre, Sydney Hospital, Sydney, NSW 2000 Australia
- School of Public Health and Community Medicine, UNSW Sydney, Kensington, NSW 2052 Australia
| | - David J. Templeton
- The Kirby Institute, UNSW Sydney, Kensington, NSW 2052 Australia
- RPA Sexual Health, Community Health, Sydney Local Health District, Camperdown, NSW 2050 Australia
- Central Clinical School, The University of Sydney, Camperdown, NSW 2006 Australia
| | - Norman Roth
- Sydney Sexual Health Centre, Sydney Hospital, Sydney, NSW 2000 Australia
| | | | - Christopher K. Fairley
- Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, VIC 3053 Australia
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004 Australia
| |
Collapse
|
10
|
Parra-Sánchez M, García-Rey S, Marcuello A, Zakariya-Yousef I, Bernal S, Pueyo I, Martín-Mazuelos E, Palomares JC. Performance of the NG OligoGen kit for the diagnosis of Neisseria gonorrhoeae: comparison with cobas 4800 assay. Diagn Microbiol Infect Dis 2015; 84:4-6. [PMID: 26508106 DOI: 10.1016/j.diagmicrobio.2015.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 09/17/2015] [Accepted: 09/30/2015] [Indexed: 11/27/2022]
Abstract
PCR assays are nowadays between the most sensitive and reliable methods for screening and diagnosing sexually transmitted infections (STIs). The aim of this study was to analyze the reliability, accuracy, and usefulness of the new NG OligoGen kit in comparison with the cobas 4800 assay for the detection of Neisseria gonorrhoeae in clinical samples. A prospective study was designed for detection of N. gonorrhoeae including urine samples (n=152), rectal (n=80), endocervical (n=67), pharyngeal (n=41), and urethral swabs (n=5) that were sent from a regional STI clinic in Seville, Spain. Samples were collected from 255 (73.9%) men and 90 women. Sensitivity, specificity, positive and negative predicative values, and kappa value for N. gonorrhoeae detection using the NG OligoGen kit were 99.6%, 100%, 100%, 99.1%, and 0.99, respectively. Statistical data obtained in this study confirm the usefulness and reliable results of this new assay.
Collapse
Affiliation(s)
- M Parra-Sánchez
- Unit of Infectious Disease and Clinical Microbiology, Valme University Hospital, Seville, Spain.
| | - S García-Rey
- Unit of Infectious Disease and Clinical Microbiology, Valme University Hospital, Seville, Spain.
| | - A Marcuello
- Operon Inmuno & Molecular Diagnostics, Cuarte de Huerva, Zaragoza, Spain.
| | - I Zakariya-Yousef
- Unit of Infectious Disease and Clinical Microbiology, Valme University Hospital, Seville, Spain.
| | - S Bernal
- Unit of Infectious Disease and Clinical Microbiology, Valme University Hospital, Seville, Spain.
| | - I Pueyo
- Center of Sexually Transmitted Infections of Seville, Seville, Spain.
| | - E Martín-Mazuelos
- Unit of Infectious Disease and Clinical Microbiology, Valme University Hospital, Seville, Spain.
| | - J C Palomares
- Unit of Infectious Disease and Clinical Microbiology, Valme University Hospital, Seville, Spain.
| |
Collapse
|
11
|
Supplementary testing is not required in the cobas 4800 CT/NG test for Neisseria gonorrhoeae weak-positive urogenital samples. J Clin Microbiol 2014; 53:327-8. [PMID: 25392357 DOI: 10.1128/jcm.01976-14] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Weak-positive Neisseria gonorrhoeae nucleic acid amplification test results are difficult to interpret. We show that the frequency of unconfirmed N. gonorrhoeae results from the cobas 4800 test rises exponentially after 38.0 cycles, where the likelihood of an unconfirmed result exceeds 29%. Supplementary testing of such samples should be avoided; instead, treatment should be based on clinical pretest probability.
Collapse
|
12
|
Moore JS, Gaukrodger N, Bignardi G. Neisseria gonorrhoeaeconfirmatory testing: helpful or a hindrance? Sex Transm Infect 2014; 90:595. [DOI: 10.1136/sextrans-2014-051802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
13
|
Cassell JA. Highlights from this issue. Br J Vener Dis 2014. [DOI: 10.1136/sextrans-2014-051651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|